Focused on
Growth and Innovation
"Patients are at the heart
of what we do"
Investor presentation
January 10, 2022
Table of contents
- Executive summary
- Five reasons to invest
- Portfolio
- Antifungal
- Cresemba® (isavuconazole)
- Antibiotic
- Zevtera® (ceftobiprole)
- Oncology
- Derazantinib
- Lisavanbulin (BAL101553)
- BAL0891
- Financials & Outlook
- Appendix
Focused on Growth and Innovation | Confidential/proprietary information of Basilea Pharmaceutica International Ltd. - not for distribution | 2 |
Executive summary
Experienced leadership team
Focused on Growth and Innovation | Confidential/proprietary information of Basilea Pharmaceutica International Ltd. - not for distribution | 4 |
At a glance
- Well funded, commercial-stage biopharmaceutical company with significantly growing cash flows from commercialized products
- Focused in the areas of oncology and infectious diseases
- Potential for sustainable growth and value creation based on commercialized brands and an innovative pipeline
- Experienced people with the proven expertise to take compounds from research to market
- Two revenue generating hospital anti-infective brands, Cresemba® and Zevtera® and three oncology drug candidates
- Recognized ability to establish and manage partnerships in both the development and commercial phase, providing access to international markets
- Listed on SIX Swiss Stock Exchange, SIX: BSLN
- Based in life sciences hub, Basel, Switzerland
Focused on Growth and Innovation | Confidential/proprietary information of Basilea Pharmaceutica International Ltd. - not for distribution | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Basilea Pharmaceutica AG published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 January 2022 06:27:01 UTC.